Cargando…
The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis
Tofisopam is a member of the 2,3-benzodiazepine compound family which is marketed for the treatment of anxiety in some European countries. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site of the γ-aminobutyric acid receptor and its psychopha...
Autores principales: | Rundfeldt, Chris, Socała, Katarzyna, Wlaź, Piotr |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993883/ https://www.ncbi.nlm.nih.gov/pubmed/20967473 http://dx.doi.org/10.1007/s00702-010-0507-3 |
Ejemplares similares
-
Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the antidepressant activity of amitriptyline but not desipramine, in the forced swim test in mice
por: Socała, Katarzyna, et al.
Publicado: (2012) -
Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in mice
por: Poleszak, Ewa, et al.
Publicado: (2011) -
Tofisopam as an alternative intervention in organic catatonia: An open label study
por: Ipsita, Pattnaik Jigyansa, et al.
Publicado: (2022) -
Role of Tofisopam in Post COVID Neuro-psychiatric Sequelae: A Case
Series
por: Pattnaik, Jigyansa ipsita, et al.
Publicado: (2021) -
Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra
por: Rahardjo, Harrina E, et al.
Publicado: (2021)